- RUXOLITINIB FOR THE TREATMENT OF MYELOFIBROSIS
[作者：Ostojic, A; Vrhovac, R; Verstovsek, S,期刊：Drugs of today, 页码：817-827 , 文章类型： Article，,卷期：2011年47-11]
- Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neop...
- TELAPREVIR: LOOKING FOR A SUSTAINED VIROLOGIC RESPONSE IN HEPATITIS C VIRUS INFECTION
[作者：Nehra, V; Rizza, SA; Talwani, R; Temesgen, Z,期刊：Drugs of today, 页码：829-837 , 文章类型： Article，,卷期：2011年47-11]
- Telaprevir, a hepatitis C virus (HCV) NS3/NS4A protease inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of chronic HCV genotype 1 infection. When given in combination with pegy...
- AN UPDATE ON EXENATIDE, A NOVEL THERAPEUTIC OPTION FOR PATIENTS WITH TYPE 2 DIABETES
[作者：Crasto, W; Khunti, K; Davies, MJ,期刊：Drugs of today, 页码：839-856 , 文章类型： Review，,卷期：2011年47-11]
- Exenatide, a synthetic glucagon GLP-1 receptor agonist, belongs to a new class of agents approved as a treatment option in patients with poorly controlled type 2 diabetes not adequately controlled on oral antidiabetic ag...
- MULTI-TARGETED TYROSINE KINASE INHIBITORS IN CLINICAL DEVELOPMENT: FOCUS ON XL-184 (CABOZANTINIB)
[作者：Bowles, DW; Kessler, ER; Jimeno, A,期刊：Drugs of today, 页码：857-868 , 文章类型： Review，,卷期：2011年47-11]
- XL-184 (cabozantinib) is a novel, small-molecule, multi-targeted receptor tyrosine kinase inhibitor with particular activity against hepatocyte growth factor receptor (tyrosine-protein kinase Met), vascular endothelial g...
|